These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 16024120)

  • 1. The sensitivity of dose distributions for organ motion and set-up uncertainties in prostate IMRT.
    Bos LJ; van der Geer J; van Herk M; Mijnheer BJ; Lebesque JV; Damen EM
    Radiother Oncol; 2005 Jul; 76(1):18-26. PubMed ID: 16024120
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the dosimetric impact of non-exclusion of the rectum from the boost PTV in IMRT treatment plans for prostate cancer patients.
    Kassim I; Dirkx ML; Heijmen BJ
    Radiother Oncol; 2009 Jul; 92(1):62-7. PubMed ID: 19278745
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simplified intensity-modulated arc therapy for dose escalated prostate cancer radiotherapy.
    Bauman G; Gete E; Chen JZ; Wong E
    Med Dosim; 2004; 29(1):18-25. PubMed ID: 15023389
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of spatial dose gradients and probability density function to evaluate the effect of internal organ motion for prostate IMRT treatment planning.
    Jiang R; Barnett RB; Chow JC; Chen JZ
    Phys Med Biol; 2007 Mar; 52(5):1469-84. PubMed ID: 17301465
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of toxicity in patients with high risk prostate cancer treated with intensity-modulated pelvic radiation therapy and simultaneous integrated dose escalation to prostate area.
    Arcangeli S; Saracino B; Petrongari MG; Gomellini S; Marzi S; Landoni V; Gallucci M; Sperduti I; Arcangeli G
    Radiother Oncol; 2007 Aug; 84(2):148-55. PubMed ID: 17692416
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Persistently better treatment planning results of intensity-modulated (IMRT) over conformal radiotherapy (3D-CRT) in prostate cancer patients with significant variation of clinical target volume and/or organs-at-risk.
    Fenoglietto P; Laliberte B; Allaw A; Ailleres N; Idri K; Hay MH; Moscardo CL; Gourgou S; Dubois JB; Azria D
    Radiother Oncol; 2008 Jul; 88(1):77-87. PubMed ID: 18215434
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparing 3DCRT and inversely optimized IMRT planning for head and neck cancer: equivalence between step-and-shoot and sliding window techniques.
    Longobardi B; De Martin E; Fiorino C; Dell'oca I; Broggi S; Cattaneo GM; Calandrino R
    Radiother Oncol; 2005 Nov; 77(2):148-56. PubMed ID: 16260056
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of biologically equivalent dose-volume parameters for the treatment of prostate cancer with concomitant boost IMRT versus IMRT combined with brachytherapy.
    Pieters BR; van de Kamer JB; van Herten YR; van Wieringen N; D'Olieslager GM; van der Heide UA; Koning CC
    Radiother Oncol; 2008 Jul; 88(1):46-52. PubMed ID: 18378028
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of geometric uncertainties on evaluation of treatment techniques for prostate cancer.
    Craig T; Wong E; Bauman G; Battista J; Van Dyk J
    Int J Radiat Oncol Biol Phys; 2005 Jun; 62(2):426-36. PubMed ID: 15890584
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does intensity modulated radiation therapy (IMRT) prevent additional toxicity of treating the pelvic lymph nodes compared to treatment of the prostate only?
    Guckenberger M; Baier K; Richter A; Vordermark D; Flentje M
    Radiat Oncol; 2008 Jan; 3():3. PubMed ID: 18190681
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IMRT versus conventional 3DCRT on prostate and normal tissue dosimetry using an endorectal balloon for prostate immobilization.
    Vlachaki MT; Teslow TN; Amosson C; Uy NW; Ahmad S
    Med Dosim; 2005; 30(2):69-75. PubMed ID: 15922172
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Strategies for online organ motion correction for intensity-modulated radiotherapy of prostate cancer: prostate, rectum, and bladder dose effects.
    Rijkhorst EJ; Lakeman A; Nijkamp J; de Bois J; van Herk M; Lebesque JV; Sonke JJ
    Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):1254-60. PubMed ID: 19857789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of changing technique, dose, and PTV margin on therapeutic ratio during prostate radiotherapy.
    Huang SH; Catton C; Jezioranski J; Bayley A; Rose S; Rosewall T
    Int J Radiat Oncol Biol Phys; 2008 Jul; 71(4):1057-64. PubMed ID: 18339487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypofractionated intensity-modulated arc therapy for lymph node metastasized prostate cancer.
    Fonteyne V; De Gersem W; De Neve W; Jacobs F; Lumen N; Vandecasteele K; Villeirs G; De Meerleer G
    Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):1013-20. PubMed ID: 19386427
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dosimetric consequences of the application of off-line setup error correction protocols and a hull-volume definition strategy for intensity modulated radiotherapy of prostate cancer.
    Baum C; Birkner M; Alber M; Paulsen F; Nüsslin F
    Radiother Oncol; 2005 Jul; 76(1):35-42. PubMed ID: 16019092
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Feasibility of IMRT to cover pelvic nodes while escalating the dose to the prostate gland: dosimetric data on 35 consecutive patients.
    Bayouth JE; Pena J; Culp L; Brack C; Sanguineti G
    Med Dosim; 2008; 33(3):180-90. PubMed ID: 18674682
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of daily setup measurements and corrections on the estimated delivered dose during IMRT treatment of prostate cancer patients.
    van Haaren PM; Bel A; Hofman P; van Vulpen M; Kotte AN; van der Heide UA
    Radiother Oncol; 2009 Mar; 90(3):291-8. PubMed ID: 19195732
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Normal tissue complication probability: does simultaneous integrated boost intensity-modulated radiotherapy score over other techniques in treatment of prostate adenocarcinoma.
    Basu KS; Bahl A; Subramani V; Sharma DN; Rath GK; Julka PK
    J Cancer Res Ther; 2009; 5(2):78-84. PubMed ID: 19542662
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II trial for the optimisation of treatment position in the radiation therapy of prostate cancer.
    O'Neill L; Armstrong J; Buckney S; Assiri M; Cannon M; Holmberg O
    Radiother Oncol; 2008 Jul; 88(1):61-6. PubMed ID: 18453021
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A case study of radiotherapy planning for a bilateral metal hip prosthesis prostate cancer patient.
    Su A; Reft C; Rash C; Price J; Jani AB
    Med Dosim; 2005; 30(3):169-75. PubMed ID: 16112469
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.